ACADIA Pharmaceuticals (MEX:ACAD) YoY EPS Growth: 4.25% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ACAD ACADIA Pharmaceuticals Inc MEX:ACAD
75 GF Score
Price MXN499.00
GF Value MXN354.08
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals YoY EPS Growth?

ACADIA Pharmaceuticals MEX:ACAD -3.11% 75 YoY EPS Growth is 4.25% as of Jun. 2026. GuruFocus rates MEX:ACAD with a GF Score™ of 75/100 and a GF Value™ of MXN354.08 (Significantly Overvalued). The stock has 10 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. ACADIA Pharmaceuticals's YoY EPS Growth for the quarter that ended in Jun. 2026 was 4.25%.

ACADIA Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was MXN3.14.

ACADIA Pharmaceuticals YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for ACADIA Pharmaceuticals's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals YoY EPS Growth Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.51 -21.29 75.96 551.66 46.01

ACADIA Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.77 95.66 60.62 -83.96 4.25
MEX:ACAD
75GF Score
ACADIA Pharmaceuticals Inc MEX:ACAD
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACADIA Pharmaceuticals YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

ACADIA Pharmaceuticals's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(41.413-28.364)/ | 28.364 |
=46.01 %

ACADIA Pharmaceuticals's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(3.141-3.013)/ | 3.013 |
=4.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 4.25% mean?
ACADIA Pharmaceuticals (MEX:ACAD) has a YoY EPS Growth of 4.25% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for ACADIA Pharmaceuticals and its competitors.
Is ACADIA Pharmaceuticals' YoY EPS Growth too high?
ACADIA Pharmaceuticals' current YoY EPS Growth is 4.25%. Overall, ACADIA Pharmaceuticals has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' YoY EPS Growth compare to PBLS and DYN?
ACADIA Pharmaceuticals' YoY EPS Growth of 4.25% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current YoY EPS Growth is 4.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN354.08, compared to a current price of MXN499.00 — trading 40.9% above its estimated fair value. The current YoY EPS Growth is 4.25%. ACADIA Pharmaceuticals' overall GF Score™ is 75/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current YoY EPS Growth is 4.25% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued. The current stock price of MXN499.00 is trading 40.9% above its estimated GF Value™ of MXN354.08. GuruFocus considers ACADIA Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for MEX:ACAD:

  • YoY EPS Growth: 4.25%
  • GF Value™: MXN354.08 vs. price of MXN499.00 (40.9% above fair value)
  • GF Score™: 75/100 with 10 warning signs

No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACADIA Pharmaceuticals Business Description

Other Exchanges ACAD:USADR6:Germany
Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
75GF Score

Get the complete analysis for MEX:ACAD

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN499.00
Price
MXN354.08
GF Value